# Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT02683525** · PHASE2 · COMPLETED · sponsor: **Sherif S. Farag** · enrollment: 37 (actual)

## Conditions studied

- Graft vs Host Disease
- Hematopoietic Stem Cell Transplantation

## Interventions

- **DRUG:** Sitagliptin

## Key facts

- **NCT ID:** NCT02683525
- **Lead sponsor:** Sherif S. Farag
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-03
- **Primary completion:** 2019-02-13
- **Final completion:** 2019-10-01
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2021-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02683525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02683525, "Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02683525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*